CannPal primed to test flagship cannabis pain relief drug for animals

CannPal primed to test flagship cannabis pain relief drug for animals

After securing key export permits from the Canadian government, CannPal Animal Therapeutics (ASX: CP1) has received its first batch of cannabis oil formulations in Australia.

The oils, which will be used in clinical trials for CannPal's lead drug candidate CPAT-01, arrived in Sydney and are currently in transit to a purpose-built research facility.

CPAT-01 is a cannabis-derived medicine which is being developed as a treatment for pain in companion animals, an alternative to non-steroidal anti-inflammatory medications which often incur a long list of side effects.

CannPal is set to test the drug in two phases, with a total of 59 dogs enrolled for treatment beginning on April 2.

CannPal founder and managing director Layton Mills says the global market for pain treatment in companion is worth more than US$1.4 billion, one which his company is now closer to cornering.

"CannPal is delighted to have successfully imported the oils for our first clinical trial for CPAT-01," says Mills.

"With the oils now in Australia and the dog selection complete we are all set to commence the live phase of our clinical research.

"Our study is the first of its kind in Australia and is one that we hope will result in the creation of a safe, efficacious pain treatment for companion animals that will meet full regulatory approval."

The company aims to treat common conditions in animals including arthritis, cancer and tumours, using safe solutions to alleviate symptoms including nausea, loss of appetite, depression and internal bleeding.

At the beginning of 2018, CannPal received its medical cannabis import license from the Office of Drug Control in Australia.

The company listed on the ASX in late October 2017 and has since gained small-medium enterprise (SME) status by the European Medicines Agency.

This opens the company up to administrative and financial assistance for the development of its drugs in Europe.

At the time of writing (11:03am AEST) CannPal shares dipped a slight 3.9 per cent to trade at $0.24.

Photo courtesy of Captain Cruise @captaincuise on Instagram.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Get our daily business news

Sign up to our free email news updates.

 
Unpacking equity: Finding your funding fit
Partner Content
Armed with a growing business and a great opportunity, a business owner’s next challe...
Australian Business Growth Fund
Advertisement

Related Stories

Big-name retailers among buyers interested in scooping up Godfreys Group

Big-name retailers among buyers interested in scooping up Godfreys Group

Buyers have begun circling embattled vacuum cleaner retailer G...

More tradies chasing fewer jobs drives Hipages to $3.7m profit

More tradies chasing fewer jobs drives Hipages to $3.7m profit

More tradies competing for fewer jobs has propelled online tradie m...

Fortis gets green light for three projects worth $570m in Melbourne and Sydney

Fortis gets green light for three projects worth $570m in Melbourne and Sydney

Sydney-based developer Fortis, the property arm of debt and equity ...

Scentre Group retailers post record sales in 2023 as foot traffic spikes

Scentre Group retailers post record sales in 2023 as foot traffic spikes

A sharp increase in foot traffic at Scentre Group’s (ASX: SCG...